Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition. Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost. In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated patient outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. In one study of 571 patients, patients treated with the Allurion Balloon gained 5.6% in lean body mass while losing 14% of their total body weight over four months. In another study of 167 patients, patients treated with the Allurion Balloon experienced a weight reduction of 15.7% with no change in muscle mass.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALUR:
- Allurion gets ‘Notification of Issuance’ from USPTO for obesity treatment
- Lilly cuts FY24 outlook, United Rentals to acquire H&E: Morning Buzz
- Allurion Technologies to sell 841,751 shares at $2.97 in private placement
- Allurion Technologies reports preliminary Q4 revenue $5.6M, consensus $5.57M
- Allurion Technologies narrows FY24 revenue view to $32M from $30M-$35M